40 results on '"Guerrero-Ramos F"'
Search Results
2. SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with BCG-naive high-risk non–muscle-invasive bladder cancer
3. First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab + intravesical bacillus Calmette-Guérin (BCG) upfront combination in BCG-naïve high risk non-muscle invasive bladder cancer patients
4. Absence of Tumor (T0) on Second Transurethral Resection (ReTURB) Positively Impact Recurrence and Progression Risk Dynamics in a Contemporary Series of High-grade T1 Non-muscle Invasive Bladder Carcinoma Treated With Adequate Bacillus Calmette-Guérin
5. Enhancing Predictions of the EAU21 Scoring Model in High-Grade Non-Muscle Invasive Bladder Carcinoma Treated with BCG using Explainable Machine Learning Survival Ensemble
6. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis
7. BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?
8. Long-term prospective results of the Spanish multicentre experience using recirculant hyperthermic MMC with Combat BRS HIVEC system
9. 676P CABOPRE: A phase II study of cabozantinib (cabo) prior cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC)
10. Intravesical chemohyperthermia versus bacillus calmette-guerin instillation for intermediate- and high-risk non-muscle invasive bladder cancer: A systematic review and meta-analysis
11. Estudio de las infecciones relacionadas con la asistencia sanitaria tras la realización de cistectomía radical
12. Evaluation of health care-associated infections following radical cystectomy
13. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)
14. Tratamientos actuales tras fracaso a BCG en cáncer de vejiga no músculo-invasivo
15. Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: What to expect in the near future
16. New immunotherapies for high-risk non-muscle invasive bladder cancer: Current state and future perspectives
17. Nuevas inmunoterapias en el cáncer de vejiga no músculo-invasivo de alto riesgo: estado actual y perspectivas de futuro
18. Evolución de las derivaciones desde Atención Primaria a Urología tras la creación de un grupo de trabajo y la instauración de protocolos y cursos de formación continuada
19. Analysis of referrals after a synergic work between primary care and urology. Impact of joint protocol implementation and a continuing education program in our healthcare area
20. HIVEC HR: Chemohyperthermia with mitomycin C vs BCG for high-risk non-muscle invasive bladder cancer. Preliminary results from a randomized controlled trial
21. Anti-CD20 and mTOR inhibitors: Can we change the prognosis of post-transplant lymphoproliferative disorder?
22. La survie des transplantations rénales des donneurs à cœur non battant incontrôlés sous la protection normothermique : sont-ils aussi bons que les reins des donneurs à cœur battant ?
23. Tratamiento adyuvante intravesical en cáncer de vejiga no músculo invasivo: importancia de la cepa y el mantenimiento
24. Adjuvant intravesical treatment for non-muscle invasive bladder cancer: The importance of the strain and maintenance
25. Kidney transplantation from uncontrolled donation after circulatory death (IIa): Organ procurement and renal harvested over a ten year period
26. 73 Survival of kidney transplants from uncontrolled DCD donors under normothermic preservation: Are they as good as DBD kidneys?
27. 72 Kidney transplantation from donors after circulatory determination of death: Evaluation prognostic factors for delayed graft function and graft survival
28. Evolution of primary care referrals to urology. Impact of a protocol on prostate disease and continuing education
29. Evolución de las derivaciones de atención primaria a urología. Impacto de un protocolo en enfermedad prostática y de formación continuada
30. 143 Healthcare-associated urinary tract infections after endourological surgery: Risk factors, microbiological features and patterns of antibiotics resistance
31. Infecciones urinarias adquiridas en la comunidad que requieren hospitalización: factores de riesgo, características microbiológicas y resistencia a antibióticos
32. Community-associated urinary infections requiring hospitalization: Risk factors, microbiological characteristics and patterns of antibiotic resistance
33. Estudio de seguridad de la biopsia renal percutánea con aguja de calibre 16G
34. Renal biopsy with 16G needle: A safety study
35. 1012 Double kidney transplantation with organs from expanded criteria donors: Review of our series and an update of current indications
36. 678 Urinary tract infections requiring hospitalization: Risk factors, microbiological characteristics and patterns of antibiotic resistance
37. 193 How do genetic polymorphisms influence in sunitinib treated metastatic renal carcinoma? A prospective observational study and validation
38. UP-02.062 Clinical, Biochemical and Radiologic Benefit of the Treatment with Sunitinib in Monotherapy for Patients with Metastatic Castration-Resistant Prostate Cancer After Failure of Docetaxel
39. Malformación arteriovenosa renal congénita: utilidad de la resonancia magnética para el diagnóstico y abordaje endovascular
40. Congenital renal arteriovenous malformation: the value of magnetic resonance imaging for dignosis and intravascular management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.